Clinical Trial Update: FIL Study on ABVD DD-DI as Upfront Therapy in HL. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on the FIL study evaluating ABVD DD-DI as upfront therapy for Hodgkin lymphoma. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Bleomycin (bleomycin)
• Dacarbazine (dacarbazine)
• Doxorubicin (doxorubicin)
• Vinblastine (vinblastine)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Hodgkin Lymphoma | Phase 3 | Status: COMPLETED